{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-281213","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.809078+00:00","generated_at":"2026-06-22T01:06:46.103071+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Soleno reports Q3 2022 net loss of $6.1M; initiates randomized withdrawal of DCCR study for PWS","bullets":["Cash at Sep 30, 2022: $19.8M; sufficient to fund operations through H1 2023 top-line data.","Net loss Q3 2022: $6.1M ($0.76 per share) vs $8.1M ($1.53) YoY.","R&D expense decreased to $3.8M from $5.0M YoY; G&A down to $2.3M.","Initiated randomized withdrawal period of Study C602 for DCCR in PWS; top-line data expected H1 2023.","FDA acknowledged that data from the study could support NDA submission."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-281213","json":"https://secwatch.observer/filing/0001193125-22-281213.json","markdown":"https://secwatch.observer/filing/0001193125-22-281213.md","text":"https://secwatch.observer/filing/0001193125-22-281213.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312522281213/0001193125-22-281213-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312522281213/d417158d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:06:46.103071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e6df51d04d14229fced9cb6ebf756e6599ee4a8","claim":"SOLENO THERAPEUTICS INC reported the three and nine months ended September 30, 2022 results: net income Net loss for the three and nine months ended September 30, 2022, was $6.1 million and $18.6 million, or a net loss of $0, EPS a net loss of $0.76 and $2.60 per basic and diluted share.","evidence_excerpt":"Soleno Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312522281213/0001193125-22-281213-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2022"},{"label":"Net income","value":"Net loss for the three and nine months ended September 30, 2022, was $6.1 million and $18.6 million, or a net loss of $0"},{"label":"EPS","value":"a net loss of $0.76 and $2.60 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}